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Summary:
We have evaluated bone marrow morphology, percentage
of bone marrow CD34þ cells, proliferative activity of
bone marrow precursors, clonogenic assay (BFU-E and
CFU-GM) in short-term bone marrow cultures, and bone
marrow cell apoptosis, together with serum TNF-a and
IL-6, in 16 chronic, refractory RA patients, as well as in
ﬁve healthy controls. Of 16 RA patients (68.7%), 11
showed a reduced bone marrow cellularity, while it was
normal in all the controls. In RA patients, the median
percentage of CD34þ bone marrow cells, the median
percentage of proliferating bone marrow myeloid pre-
cursors, and the median number of both BFU-E and CFU-
GM colonies were signiﬁcantly lower than observed in the
controls. As far as TNF-a and IL-6 titers is concerned, the
latter did not signiﬁcantly differ from controls’ values,
while TNF-a titers were signiﬁcantly lower in healthy
controls. Finally, the median apoptotic index of early bone
marrow myeloid cells of RA patients was signiﬁcantly
higher compared with controls. These observations may
identify the biological risk factors for impaired mobiliza-
tion and/or engraftment when RA patients are candidates
for autologous hematopoietic stem cell grafting.
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Rheumatoid arthritis (RA) is the most common systemic
autoimmune disease, affecting 0.5–1% of the whole world
population;1 despite being a chronic evolving disease, RA
can shorten life by 5–10 years;2 furthermore, variables
reﬂecting disease severity have been demonstrated to
negatively impact on RA patients’ survival.3
Although, on the one hand, a number of different drugs
(including immunosuppressive and cytotoxic agents) may
suppress disease activity and/or palliate disease-related
symptoms, on the other hand, they also require chronic
administration, do not cure the autoimmune disease itself,
cannot prevent irreversible end organ damage, often cause
severe toxicity, and have considerable economic costs for
the individual as well as the community.4
For all these reasons, autologous hemopoietic stem cell
transplantation (aHSCT) has been proposed for the
treatment of both severe refractory RA and other life-
threatening autoimmune diseases;5–15 indeed, such thera-
peutic procedures are increasingly performed in auto-
immune disease patients, according to the European Bone
Marrow Transplantation (EBMT) registry data.16,17
Several abnormalities in the hemopoietic and immune
systems in patients with RA have been documented and
include: ineffective erythropoiesis,18 inhibition of granulo-
monocytopoiesis,19 T-cell hyporesponsiveness or anergy,20
B-cell functional abnormalities (especially decreased in vitro
immunoglobulin production),21 and functional deﬁciency
of antigen-presenting cells, at least in the synovial ﬂuid.22
Furthermore, an increased number of bone marrow
CD34þ cells in response to an abnormally high production
of G-CSF by bone marrow stroma has been recently
described by Papadaki et al.23
Since the complex immune deregulation present in
autoimmune diseases may affect bone marrow progenitor
cell development at several stages of differentiation,24
Ikehara25 et al suggested that autoimmune diseases should
be considered as primary stem cell disorders.
Furthermore, patients with long-lasting and/or severe
RA, who are ideal candidates for aHSCT, may have been
exposed for years to myelosuppressive and/or myelotoxic
drugs. Thus, impaired or altered bone marrow function,
partially intrinsic and partially iatrogenic, may have an
inﬂuence on the functional quality of circulating progenitor
cells (CPCs) to be mobilized and then autografted.
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In this in vivo study, we investigated the biologic and
functional characteristics of bone marrow hematopoietic
progenitors in severe refractory RA patients who were
candidates for aHSCT.
Patients and methods
Patients
After obtaining informed consent, 16 caucasian female
patients with severe refractory RA were enrolled into the
study.
In all patients, RA was diagnosed according to the
American College of Rheumatology criteria.26
The average age was 55 years (median 57; range 29–65);
on the average, RA duration in these patients was 112.4
months (median 84, range 23–348), that is, more than 9
years.
All patients chronically received steroids, at a median
cumulative dose of 8640mg of prednisone equivalent
(mean 20 491.71, range 350–178 290); all were still
receiving steroids at the time of enrollment into this
study.
All patients but two had received methotrexate (MTX) at
a median cumulative dose of 732.5mg (mean 1122.5, range
200–2730), 11 still under MTX treatment at the time of
their enrollment into this study.
Finally, seven patients also received cyclosporine A
(CyA), at a median cumulative dose of 78 000mg (mean
90 050, range 9100–172 750), with six still under CyA.
None of the above RA patients was treated with anti-
TNF-a or anti-IL-1 antibodies before the study.
As a parameter of disease activity, C-reactive protein
(CRP),27 measured both at the time of study entry as well
as every 3 weeks during the course of the disease, that is,
cumulative CRP, was used.
Patient characteristics are reported in Table 1.
Controls
As controls, ﬁve healthy females, adequately chosen within
the age range of RA patients (average age 52 years, median
54, range 30–70), were studied after informed consent was
obtained; all controls presented with a normal baseline
hematologic proﬁle and none was known to have evident
diseases, or were under pharmacological treatment that
could interfere with hematopoiesis.
Bone marrow cytology
Bone marrow samples were obtained from posterior iliac
crest aspirates; differential cell count was assessed by
evaluating 1000 nucleated cells from different areas of
May–Gru¨nwald–Giemsa-stained preparations. Scoring in-
cluded erythroblasts, nonproliferating (metamyelocytes,
plus band forms, plus neutrophils) and proliferating
(myeloblasts, plus promyelocytes, plus myelocytes) myeloid
cells, as previously described.28
Bone marrow CD34þ cell evaluation
The percentage of CD34þ progenitor cells in bone marrow
samples was evaluated on a Coulter Epics-XL (Coulter
International Co., Miami, FL, USA) ﬂow cytometer, using
the HPCA-2 anti-CD34 monoclonal antibody (Becton
Dickinson, Mountain View, CA, USA), according to the
‘Milan protocol’29 (Figure 1).
Flow-cytometric (FCM) analysis of proliferative activity
(S-phase) of bone marrow myeloid precursors
Single-cell suspensions were obtained from bone marrow
particles that were gently washed in saline solution, placed
into a 5ml tube containing 1ml of PBS (Sigma Chemicals,
St Louis, MO, USA), and ﬁnally disrupted by pipetting.
Light-density mononuclear cells (LDMNCs) were col-
lected after centrifugation on a Ficoll-Hypaque (Pharmacia
Table 1 Patients’ characteristics
No. Sex Age
(years)
Disease
duration
(months)
Present
ESR (mm)
Present
CRP (mg/dl)
Actual DMARDs Total steroid dose (mg) Cumulative CRP
1 F 65 23 69 15.2 GS, HCQ 350 23.85
2 F 49 36 76 6.4 MTX 7920 12.3
3 F 60 216 19 11.3 MTX 1825 n.a.
4 F 57 48 53 1 HCQ, MTX, CyA 12 562.5 84.55
5 F 57 240 41 1.8 SSZ, HCQ 178.290 56.1
6 F 58 24 96 10.9 MTX, HCQ 6275 66.3
7 F 50 216 44 9.6 GS 2190 9.6
8 F 54 96 51 2.7 MTX, SSZ 19 530 42.03
9 F 29 72 6 0.7 MTX, HCQ, CyA 12 915 63.5
10 F 50 108 70 0.6 MTX, HCQ, CyA 16 680 83.69
11 F 47 48 6 7.2 MTX, HCQ, CyA 4500 44.7
12 F 65 108 71 9.3 MTX 34 620 85.58
13 F 64 48 5 0.3 HCQ, CyA 9360 0.5
14 F 46 132 60 1 GS 11 670 n.a.
15 F 64 36 63 13.7 MTX, HCQ, CyA 4560 106.5
16 F 65 348 24 1.8 MTX 4620 21.6
ESR¼ erythrocyte sedimentation rate; CRP¼C-reactive protein; DMARDs¼ disease-modifying antirheumatic drugs; MTX¼methotrexate; HCQ¼
hydroxychloroquine; CyA¼ cyclosporine A; SSZ¼ sulfasalazine; GS¼ gold salts.
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Fine Chemicals, Piscataway, NJ, USA) density gradient
(1.077 g/cm3) in Iscove’s modiﬁed Dulbecco’s medium
(IMDM, Sigma Chemicals, St Louis, MO, USA).
The cells were further puriﬁed by removing adherent cells
and T lymphocytes as follows: a 5ml suspension of
LDMNCs at a concentration of 5 106 cells/ml in IMDM
plus 15% FCS (Sigma Chemicals, St Louis, MO, USA) was
incubated in 25 cm2 tissue culture ﬂasks (Falcon Co.,
Germany) for 60min at 371C, and nonadherent cells were
carefully collected; this procedure was repeated twice.
T-lymphocyte-depleted LDMNCs were obtained by
rosetting mononuclear cell suspensions (5 106 cells) with
2-aminoethylisothiouronium bromide (AET, Sigma Che-
micals, St. Louis, MO, USA)-treated sheep red blood cells
in a 5% suspension with IMDM; nonrosetting cells were
ﬁnally separated using a second Ficoll–Hypaque density
centrifugation.
The viability after cell separation was evaluated by the
Trypan blue (Sigma Chemicals, St Louis, MO, USA) dye-
exclusion test.
Cells were washed twice in PBS, ﬁltered through a 35-mm
pore nylon ﬁlter, resuspended in PBS and used for FCM
analyses.
The DNA staining and FCM techniques we used have
been extensively described and discussed elsewhere.30,31
Brieﬂy, cells were suspended in PBS, and drawn through
needles of decreasing diameters; the obtained suspension
was stained with propidium iodide (PI, Calbiochem,
Behring Co., San Diego, CA, USA) at a concentration of
50 mg/ml in PBS plus 0.1% Nonidet P40 (Calbiochem,
Behring Co., San Diego, CA, USA), 0 and 0.05% RNAse
(Sigma Chemicals, St Louis, Mo, USA), for 30min at room
temperature. Cell cycle analysis was carried out using a
DAKO/Partec PAS III ﬂow cytometer (Dako, Glostrup,
Denmark) under the following conditions: argon ion laser
excitation power 50mW at 488 nm, 610 nm long pass ﬁlter
for the red ﬂuorescence (PI) detector. The percentage of
cells in the S-phase of the cell cycle was thus recorded.
Clonogenic assay
Clonogenic assays were performed as described else-
where,32 with minor modiﬁcations. Brieﬂy, 2 104
LDMNCs were plated in 35-mm Petri dishes in 1ml
aliquots of IMDM containing 30% FBS (HyClone, Logan,
UT, USA), 5 105mol/l b-mercaptoethanol, 0.9% (w/v)
methylcellulose (both from Sigma Chemicals, St Louis,
MO, USA), 10 ng/ml GM-CSF (PeproTech Inc., Rocky
Hill, NJ, USA), 10 ng/ml IL-3 (Sandoz International, Basel,
Switzerland), 50 ng/ml SCF (PeproTech Inc., Rocky Hill,
NJ, USA), and 3 IU/ml erythropoietin (Boehringer-
Mannheim, Mannheim, Germany).
Since it has been reported that patients suffering from
severe rheumatoid arthritis have increased serum levels of
cytokines, such as interferon-g or TNF-a,33,34 which are
known to exert an inhibitory effect on the growth of
clonogenic progenitor cells, we also performed clonogenic
assays in which FBS was replaced by patient serum.
Cultures were incubated at 371C and 5% CO2 for 14
days; at the end of incubation, the number of BFU-E and
CFU-GM was scored using an inverted microscope.
Serum TNF-a and IL-6 titration by flow cytometry
For the quantitative titration of two serum cytokines
TNF-a and IL-6 by ﬂow cytometry, a commercial kit
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Figure 1 Identiﬁcation of bone marrow CD34þ cells by ﬂow cytometry.
Panel shows representative dot plot data illustrating the analytical method
utilized to identify CD34þ cells in bone marrow (see Materials and
methods). (a) Mononuclear cells analysis region applied to FS SS data
acquired for exclusion of granulocytes and debris (region R1). (b) The same
identiﬁed cell population after labelling with CD34 anti-MoAb (region R2).
Hematopoietic progenitor cells in RA
C Porta et al
723
Bone Marrow Transplantation
(Quantiﬂow, Bio Ergonomics, Centerville Road, MN,
USA) was used, according to the manufacturer’s instruc-
tions (Figure 2a–d).
Brieﬂy, venous blood derived from venipuncture of an
antecubital vein of the forearm was centrifuged at
2000 r.p.m. and then stored at 201C for subsequent
titrations; 500ml of blood was then vortexed for 600
together with 10 ml of TNF-a or IL-6 capture beads;
following two washings with IFA Buffer 10 , 10ml of PE-
conjugated TNF-a or IL-6 reporter antibody were added;
following incubation and washings, the samples were
analyzed using a Coulter Epics-XL (Coulter International
Co., Miami, FL, USA) equipment.35
Evaluation of bone marrow cell apoptosis
Apoptosis was measured on early bone marrow myeloid
precursors using a terminal-deoxynucleotidyl-transferase
(TdT)-mediated deoxyuridine triphosphate (dUTP) nick
end labeling (TUNEL) technique36 (Figure 3).
Brieﬂy, the In situ Cell Death Detection Kit, AP
(Boehringer-Mannheim, Germany), which contains calf
thymus TdT, ﬂuorescein-dUTP, and an alkaline phospha-
tase antiﬂuorescein sheep Fab fragment, was used accord-
ing to the manufacturer’s instructions, improved by the
ﬁxation of smears with cold acetone for 10min, and by the
omission of cell permeabilization. After the alkaline
phosphatase reaction, counterstaining was performed with
Mayer’s hematoxylin. A negative control was performed by
omitting TdT from the labelling mixture.
The apoptotic index (AI) was expressed as the percentage
of positive nuclei for 500 counted cells at a magniﬁcation of
 1000, evaluated on the same sample by two different
experienced hematologists unaware of sample origin.
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Figure 2 Flow cytometric determination of serum IL-6 and TNF-a. Panel shows representative data illustrating the analytical method (see Materials and
methods). (a,c) FS SS analysis of PE-conjugated capture beads for both cytokines. (b,d) Corresponding ﬂuorescent signals of beads (the mean channel is
determined by gating on the main peak of the beads).
Figure 3 Bone marrow smear from a RA patient; TUNEL technique. A
high percentage of immature cells shows strong nuclear reativity ( 480).
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Statistics
Traditional statistics and correlations between variables
were performed using the MS Excel software, run on an
iMac computer (Apple Computers, Cupertino, CA, USA);
differences between patients and controls were analyzed
using the Student’s t-test.
Results
Bone marrow cytology
Out of 16 patients, 11 (68.7%) showed reduced bone
marrow cellularity by direct light microscope examination
of bone marrow smears; in ﬁve, the reduction was minimal
though evident, while in six it was more marked.
In the remaining ﬁve patients, as well as in all the ﬁve
healthy controls, a normal bone marrow cellularity was
present.
Bone marrow CD34þ cells
The mean percentage of CD34þ bone marrow cells in our
RA patients was 0.25 (70.13 s.d., median 0.28, range 0.1–
0.5). This ﬁgure was signiﬁcantly (P¼ 0.003) lower than
that observed in the ﬁve healthy controls (mean 1.8770.59
s.d., median 1.89, range 0.99–2.0).
Proliferative activity (S-phase) of bone marrow myeloid
precursors
The mean percentage of proliferating bone marrow myeloid
precursors, that is, those myeloid cells in the S-phase of the
cell cycle, was 4.03 (73.28 s.d., median 2.85, range 1.5–
12.5) in our RA patients. Also, in this case, the above ﬁgure
was signiﬁcantly lower (P¼ 0.05) than that observed in the
ﬁve healthy controls (mean 9.274.36 s.d., median 7.0,
range 5.1–14.9).
Clonogenic assay
The median number of BFU-E in the RA patients was 14.5
(716.5 s.d., mean 21.2, range 3–54), a number signiﬁcantly
lower (P¼ 0.01) than that observed in the ﬁve healthy
controls (median 48713.7 s.d., mean 43.2, range 21–56).
The mean number of CFU-GM in RA patients was 21
(717 s.d., median 24, range 1–59), a ﬁgure that did not
signiﬁcantly differ (P¼ n.s.) from that observed in the ﬁve
healthy controls (mean 3874.47 s.d., median 38, range 36–
44). These data are summarized in Figure 4.
Furthermore, no statistically signiﬁcant differences were
observed between clonogenic assays with FBS or with
patient’s serum (data not shown).
Serum TNF-a and IL-6 titers
Both TNF-a and IL-6 were detected in the serum of
our RA patients; indeed, the mean TNF-a titers were
9.68 pg/ml (711.02 s.d., median 7, range 2–50) and IL-6
146.63 (7406.05 s.d., median 14.75, range 2.8–1600),
respectively.
TNF-a titers were signiﬁcantly lower (P¼ 0.01) in the
ﬁve healthy controls (mean 2.2670.25 s.d., median 2.2,
range 2.1–2.7) than in RA patients. IL-6 titers were lower
(mean 4.271.12 s.d., median 3.6, range 3.3–5.9), but not
signiﬁcantly different, from the above patients’ values. A
wide dispersion of IL-6 titers was found in patients with
RA, according to the different disease activity score.
Bone marrow cell apoptosis
The mean apoptotic index of early bone marrow myeloid
cells of our RA patients was 43 (711.76 s.d., median 41.65,
range 23–60), a ﬁgure that was signiﬁcantly (P¼ 0.0005)
higher compared with results in the ﬁve healthy controls
(mean 11.771.09 s.d., mean 12, range 10–13).
Parameters of bone marrow function according to disease
history
No statistically signiﬁcant correlations were found when
bone marrow function parameters, that is, number of
CD34þ cells, proliferative activity of myeloid precursors,
CFU-GM and BFU-E in vitro growth, as well as bone
marrow apoptosis, were plotted against disease duration
and against parameters of disease activity, including
cumulative CRP and disease activity score. When patients
under MTX treatment were compared to RA patients who
were not receiving MTX, no signiﬁcant differences were
found in the bone marrow function parameters (Table 2).
Discussion
Although RA is a systemic autoimmune disease character-
ized mainly by a chronic destructive polyarthritis, growing
evidence suggests that the bone marrow may also be
actively involved in its pathophysiology, so that RA can be
considered as a bone marrow,37 or a primary stem cell,
disorder. 25 This has reinforced the rationale, initially based
0
10
20
30
40
50
60
70
80
CFU-GM BFU-E
p = n.s. p = 0.01
RA pts.
RA pts.
Controls
Controls
Figure 4 Clonogenic assay. In RA patients, the median number of BFU-
E was signiﬁcantly lower than that observed in the controls, while the
median number of CFU-GM in RA patients did not signiﬁcantly differ
from that of controls.
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only on animal data and anectodical case reports, for the
use of hematopoietic stem cell transplantation in the
treatment of RA.8,17,25
Thus, it is clearly important to ascertain if the chronic
inﬂammatory process,38 and/or the sustained immunosup-
pressive therapy commonly employed in these patients,39
could negatively impact either on mobilization of stem cells
into the blood or, especially, on their engraftment after
transplantation.
Indeed, besides their absolute number,40 the functional
quality of the autologous CPCs mobilized into the
peripheral blood, including their cell cycle status,41–43
apoptosis,44,45 and phenotype,46,47 is a key element in the
success of the autografting procedure, as already demon-
strated in both solid and hematologic malignancies.
For all these reasons, we have studied the quantitative
and qualitative characteristics of bone marrow hemato-
poietic progenitor cells in 16 RA patients who were
candidates for autologous stem cell transplantation.
From a morphological viewpoint, the majority of our
patients showed a markedly reduced bone marrow cellu-
larity with respect to healthy controls.
Similarly, ﬂow cytometry showed a signiﬁcantly lower
percentage of CD34þ bone marrow cells and suppressed
proliferative activity (evaluated through the determination
of DNA S-phase) of bone marrow myeloid precursors,
compared with controls. Furthermore, the median apop-
totic index of early bone marrow myeloid precursors
(evaluated by TUNEL analysis) was signiﬁcantly higher
compared to controls. These results are in agreement with
recent observations by Papadaki et al.48 In contrast to the
observations of these authors using the clonogenic assay,48
we were able to identify only suppression of BFU-E, and
not of CFU-GM, in our RA patients, when either FBS or
patients’ serum was used. Indeed, our observation could
explain the high incidence of anemia in RA patients, in
contrast to neutropenia.49
We studied IL-650 and TNF-a51 as the possible mediators
of inﬂammation, potentially able to contribute to bone
marrow function suppression and apoptosis. Both cyto-
kines were detected by a FCM technique in the serum
of patients and controls. No signiﬁcant differences
were found in IL-6 serum levels between patients and
controls, probably due to the limited number of cases
studied and a wide variation related to disease activity.
Nonetheless, signiﬁcantly higher serum TNF-a titres
were found in RA patients independently of the disease
activity score. The latter observation is in agreement with
the results of Papadaki et al, who showed high TNF-a
levels in the supernatant of cultured bone marrow stromal
cells.48
The chronic use of an immunosuppressive drug such as
MTX could also explain the biological alterations reported
above. We compared the bone marrow function parameters
of patients receiving MTX treatment at the time of the
study, with those of patients who were not receiving MTX.
Since no differences were observed between these two
groups, we can conclude that the observed alterations are
not only due to MTX treatment.
Taken together, these observations may allow the
identiﬁcation of ‘biological risk factors’ for impaired
mobilization and/or a delayed engraftment when RA
patients with the above clinical characteristics, that is, long
disease duration, active disease, and heavy pretreatment,
are candidates for high-dose chemotherapy and autologous
stem cell grafting.
As far as mobilization is concerned, available data are
controversial; indeed, even though CPCs harvested from
patients with severe RA have already been demonstrated to
signiﬁcantly differ in terms of composition from those of
normal individuals, in vitro studies supported normal CPC
function,52 and at least one in vivo study reported no
mobilization impairment in RA patients.53 Furthermore,
we have previously demonstrated that CD34 mobilization
by G-GSF alone is effective in RA but lower than in
healthy donors, while the combined use of an intermediate
dose of cyclophosphamide and G-CSF as mobilization
regimen appears to be more effective.54
We conclude that the combined use of chemotherapy,
hematopoietic growth factors, and antagonists of myelo-
suppressive cytokines, for example, anti-TNF-a mono-
clonal antibody, warrants further investigation.
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